We have located links that may give you full text access.
Noncanonical regulation of HOIL-1 on cancer stemness and sorafenib resistance identifies pixantrone as a novel therapeutic agent for hepatocellular carcinoma.
Hepatology : Official Journal of the American Association for the Study of Liver Diseases 2023 October 12
BACKGROUND AIMS: Cancer stem cells (CSCs) contribute to therapy resistance in hepatocellular carcinoma (HCC). Linear ubiquitin chain assembly complex (LUBAC) has been reported to accelerate the progression of cancers, yet its role in the sorafenib response of HCC is poorly defined. Herein, we investigated the impact of LUBAC on sorafenib resistance and the CSC properties of HCC, and explored the potential targeted drugs.
METHODS: The effect of LUBAC on sorafenib response was evaluated. The role of HOIL-1 in promoting sorafenib resistance and the CSCs properties of HCC were investigated in vitro and in vivo. The mechanism of HOIL-1 in regulating Numb/Notch1 axis was explored using mass spectrometry, co-immunoprecipitation, and western blot. HOIL-1 inhibitors were screened using Autodock Vina, and the anti-tumor effects of pixantrone were evaluated.
RESULTS: HOIL-1 contributed to LUBAC-mediated HCC sorafenib resistance independent of its ubiquitin ligase activity. Upregulated HOIL-1 expression enhanced the CSC properties of HCC. Mechanistically, HOIL-1 promoted sorafenib resistance and the CSC properties of HCC via Notch1 signaling. The A64/Q65 residues of HOIL-1 bound with the K78 residue of Numb to impair Numb-mediated Notch1 lysosomal degradation. Notably, pixantrone interrupted HOIL-1/Numb interaction to inhibit Notch1 signaling and CSC properties by targeting the Q65 residue of HOIL-1. Moreover, pixantrone exerted synergistic effects with sorafenib for HCC therapeutic.
CONCLUSION: HOIL-1 is critical in promoting sorafenib resistance and CSC properties of HCC through Notch1 signaling. Pixantrone targeting HOIL-1 restrains the sorafenib resistance and provides a potential therapeutic intervention for HCC.
METHODS: The effect of LUBAC on sorafenib response was evaluated. The role of HOIL-1 in promoting sorafenib resistance and the CSCs properties of HCC were investigated in vitro and in vivo. The mechanism of HOIL-1 in regulating Numb/Notch1 axis was explored using mass spectrometry, co-immunoprecipitation, and western blot. HOIL-1 inhibitors were screened using Autodock Vina, and the anti-tumor effects of pixantrone were evaluated.
RESULTS: HOIL-1 contributed to LUBAC-mediated HCC sorafenib resistance independent of its ubiquitin ligase activity. Upregulated HOIL-1 expression enhanced the CSC properties of HCC. Mechanistically, HOIL-1 promoted sorafenib resistance and the CSC properties of HCC via Notch1 signaling. The A64/Q65 residues of HOIL-1 bound with the K78 residue of Numb to impair Numb-mediated Notch1 lysosomal degradation. Notably, pixantrone interrupted HOIL-1/Numb interaction to inhibit Notch1 signaling and CSC properties by targeting the Q65 residue of HOIL-1. Moreover, pixantrone exerted synergistic effects with sorafenib for HCC therapeutic.
CONCLUSION: HOIL-1 is critical in promoting sorafenib resistance and CSC properties of HCC through Notch1 signaling. Pixantrone targeting HOIL-1 restrains the sorafenib resistance and provides a potential therapeutic intervention for HCC.
Full text links
Related Resources
Trending Papers
Angiotensin Receptor Blocker-Neprilysin Inhibitor for Heart Failure with Reduced Ejection Fraction.Pharmacological Research : the Official Journal of the Italian Pharmacological Society 2024 May 12
Drug Therapy for Acute and Chronic Heart Failure with Preserved Ejection Fraction with Hypertension: A State-of-the-Art Review.American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions 2024 April 5
Guillain-Barré syndrome: History, pathogenesis, treatment, and future directions.European Journal of Neurology 2024 May 17
The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment.Cardiac Failure Review 2024
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app